vs

Side-by-side financial comparison of REDWOOD TRUST INC (RWT) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $25.9M, roughly 1.4× REDWOOD TRUST INC). REDWOOD TRUST INC runs the higher net margin — 77.2% vs -304.2%, a 381.5% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs -6.1%). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs -41.0%).

Redwood Trust Inc is a specialized U.S.-headquartered real estate investment trust (REIT). It manages investment portfolios covering residential and commercial mortgage loans, mortgage-backed securities, and real estate credit assets. Its core segments include residential mortgage lending, commercial real estate credit, and investment management, serving institutional investors and real estate market stakeholders.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

RWT vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.4× larger
RXRX
$35.5M
$25.9M
RWT
Growing faster (revenue YoY)
RXRX
RXRX
+687.8% gap
RXRX
681.7%
-6.1%
RWT
Higher net margin
RWT
RWT
381.5% more per $
RWT
77.2%
-304.2%
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
-41.0%
RWT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
RWT
RWT
RXRX
RXRX
Revenue
$25.9M
$35.5M
Net Profit
$20.0M
$-108.1M
Gross Margin
59.8%
Operating Margin
-304.8%
Net Margin
77.2%
-304.2%
Revenue YoY
-6.1%
681.7%
Net Profit YoY
402.6%
39.6%
EPS (diluted)
$0.11
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RWT
RWT
RXRX
RXRX
Q4 25
$25.9M
$35.5M
Q3 25
$15.0M
$5.2M
Q2 25
$13.8M
$19.2M
Q1 25
$27.9M
$14.7M
Q4 24
$27.6M
$4.5M
Q3 24
$25.5M
$26.1M
Q2 24
$67.4M
$14.4M
Q1 24
$74.5M
$13.8M
Net Profit
RWT
RWT
RXRX
RXRX
Q4 25
$20.0M
$-108.1M
Q3 25
$-7.7M
$-162.3M
Q2 25
$-98.5M
$-171.9M
Q1 25
$16.1M
$-202.5M
Q4 24
$-6.6M
$-178.9M
Q3 24
$14.8M
$-95.8M
Q2 24
$15.5M
$-97.5M
Q1 24
$30.3M
$-91.4M
Gross Margin
RWT
RWT
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
RWT
RWT
RXRX
RXRX
Q4 25
-304.8%
Q3 25
-9.0%
-3327.6%
Q2 25
-679.0%
-916.8%
Q1 25
80.2%
-1297.9%
Q4 24
-1.3%
-4042.4%
Q3 24
86.1%
-377.1%
Q2 24
30.3%
-697.4%
Q1 24
41.3%
-698.4%
Net Margin
RWT
RWT
RXRX
RXRX
Q4 25
77.2%
-304.2%
Q3 25
-51.4%
-3135.3%
Q2 25
-712.0%
-894.2%
Q1 25
57.8%
-1373.3%
Q4 24
-24.0%
-3935.5%
Q3 24
58.1%
-367.5%
Q2 24
23.0%
-676.6%
Q1 24
40.6%
-662.4%
EPS (diluted)
RWT
RWT
RXRX
RXRX
Q4 25
$0.11
$-0.17
Q3 25
$-0.08
$-0.36
Q2 25
$-0.76
$-0.41
Q1 25
$0.10
$-0.50
Q4 24
$-0.08
$-0.56
Q3 24
$0.09
$-0.34
Q2 24
$0.10
$-0.40
Q1 24
$0.21
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RWT
RWT
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$255.7M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$982.6M
$1.1B
Total Assets
$23.7B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RWT
RWT
RXRX
RXRX
Q4 25
$255.7M
$743.3M
Q3 25
$226.3M
$659.8M
Q2 25
$302.0M
$525.1M
Q1 25
$259.9M
$500.5M
Q4 24
$245.2M
$594.4M
Q3 24
$253.7M
$427.6M
Q2 24
$275.6M
$474.3M
Q1 24
$275.4M
$296.3M
Total Debt
RWT
RWT
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
$1.7B
Stockholders' Equity
RWT
RWT
RXRX
RXRX
Q4 25
$982.6M
$1.1B
Q3 25
$999.0M
$1.0B
Q2 25
$1.1B
$919.1M
Q1 25
$1.2B
$933.9M
Q4 24
$1.2B
$1.0B
Q3 24
$1.2B
$524.6M
Q2 24
$1.2B
$584.4M
Q1 24
$1.2B
$401.2M
Total Assets
RWT
RWT
RXRX
RXRX
Q4 25
$23.7B
$1.5B
Q3 25
$22.6B
$1.4B
Q2 25
$21.3B
$1.3B
Q1 25
$19.9B
$1.3B
Q4 24
$18.3B
$1.4B
Q3 24
$18.4B
$726.5M
Q2 24
$16.5B
$775.9M
Q1 24
$15.1B
$557.8M
Debt / Equity
RWT
RWT
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24
1.39×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RWT
RWT
RXRX
RXRX
Operating Cash FlowLast quarter
$-10.1B
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
-504.15×
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RWT
RWT
RXRX
RXRX
Q4 25
$-10.1B
$-46.1M
Q3 25
$-2.7B
$-117.4M
Q2 25
$-2.1B
$-76.4M
Q1 25
$-2.0B
$-132.0M
Q4 24
$-5.9B
$-115.4M
Q3 24
$-2.1B
$-59.2M
Q2 24
$-2.0B
$-82.2M
Q1 24
$-954.2M
$-102.3M
Free Cash Flow
RWT
RWT
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
RWT
RWT
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
RWT
RWT
RXRX
RXRX
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
8.2%
Q1 24
48.2%
Cash Conversion
RWT
RWT
RXRX
RXRX
Q4 25
-504.15×
Q3 25
Q2 25
Q1 25
-120.92×
Q4 24
Q3 24
-140.86×
Q2 24
-126.56×
Q1 24
-31.53×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons